CDKN2B-AS1 and neoplasm: ANRIL mRNA expression showed no significant difference regarding gender, age, pathological type, tumor volume, multicenteric cancer foci or surgical procedure (all P > 0.05), but there was a significant difference in ANRIL mRNA expression for tumor node metastasis (TNM) staging and LNM (both P < 0.01) (Table 1).